Management of complicated tumor response to tyrosine-kinase inhibitors in gastrointestinal stromal tumors.
Fabio TirottaElena FumagalliChiara ColomboCarlo MorosiMarta BarisellaStefano RadaelliAnna M FrezzaPaolo G CasaliAlessandro GronchiMarco FiorePublished in: Journal of surgical oncology (2019)
While the risk of CTR in early metastatic patients is virtually nil, patients with locally advanced disease should be monitored carefully. CTR as a consequence of TKI therapy do not prevent patients receiving a potentially curative surgery.
Keyphrases
- squamous cell carcinoma
- end stage renal disease
- locally advanced
- rectal cancer
- prognostic factors
- ejection fraction
- newly diagnosed
- chronic kidney disease
- small cell lung cancer
- minimally invasive
- peritoneal dialysis
- neoadjuvant chemotherapy
- tyrosine kinase
- stem cells
- patient reported outcomes
- chronic myeloid leukemia
- mesenchymal stem cells
- coronary artery bypass
- bone marrow
- acute coronary syndrome